<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249310</url>
  </required_header>
  <id_info>
    <org_study_id>1237-0100</org_study_id>
    <nct_id>NCT04249310</nct_id>
  </id_info>
  <brief_title>Early Intervention Efficacy in COPD</brief_title>
  <official_title>Early Intervention Effectiveness of Tiotropium / Olodaterol Compared to Tiotropium in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the time to escalation to triple therapy among the Japanese&#xD;
      Chronic obstructive pulmonary disease (COPD) patients newly initiating therapy with a&#xD;
      combination of Olodaterol and Tiotropium (herein referred to as Tio/Olo) using real world&#xD;
      data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2020</start_date>
  <completion_date type="Actual">August 12, 2020</completion_date>
  <primary_completion_date type="Actual">August 12, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Triple Therapy Initiation</measure>
    <time_frame>From index date (cohort entry date) until first occurence of event, up to 42 months.</time_frame>
    <description>Time to triple therapy initiation (first event per patient) defined as any fixed dose combination of Long-acting muscarinic antagonists (LAMA) / Long-acting beta agonist (LABA) / Inhaled Corticosteroid (ICS) or any concurrent use for 30 consecutive days of the following:&#xD;
any LAMA/LABA fixed dose combination + any ICS single formulation&#xD;
any LAMA single formulation + any LABA/ICS fixed dose combination&#xD;
any LAMA single formulation + any LABA single formulation + any ICS single formulation.&#xD;
Patients will be censored if they had an occurrence of any of the following: outcome (initiation of triple therapy), death, or end of data. The analysis will use an intention-to-treat censoring approach, which does not account for treatment change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>From index date until first occurence of event, up to 42 months.</time_frame>
    <description>Time to First Moderate or Severe COPD Exacerbation. Moderate exacerbation is defined as an outpatient visit with a diagnosed code for COPD in any field + a prescription for an oral corticosteroid or an antibiotic for respiratory infections. Severe exacerbations will be defined as a hospitalization with a primary diagnosis for COPD.&#xD;
Patients will be censored if they had an occurrence of any of the following: outcome (initiation of triple therapy), death, or end of data. The analysis will use an intention-to-treat censoring approach, which does not account for treatment change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</measure>
    <time_frame>From index date until first occurence of event, up to 42 months.</time_frame>
    <description>Number of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations.&#xD;
Moderate exacerbation is defined as an outpatient visit with a diagnosed code for COPD in any field + a prescription for an oral corticosteroid or an antibiotic for respiratory infections. Severe exacerbations will be defined as a hospitalization with a primary diagnosis for COPD.&#xD;
Patients will be censored if they had an occurrence of any of the following: outcome (initiation of triple therapy), death, or end of data. The analysis will use an intention-to-treat censoring approach, which does not account for treatment change.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">6788</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiotropium/Olodaterol</arm_group_label>
    <description>Combination of Tiotropium and Olodaterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium/Olodaterol</intervention_name>
    <description>Soft Mist Inhaler product</description>
    <arm_group_label>Tiotropium/Olodaterol</arm_group_label>
    <other_name>Spiolto®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Soft Mist Inhaler product</description>
    <arm_group_label>Tiotropium</arm_group_label>
    <other_name>Spiriva®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study cohort will include all patients who initiate Tiotropium/Olodaterol (Tio/Olo) or&#xD;
        Tiotropium (Tio) during the patient selection period. Initiation (new use) will be&#xD;
        determined based on no prescription claims for Tio/Olo or Tio during the baseline period or&#xD;
        during all available data prior to cohort entry date. All patients will additionally be&#xD;
        required to have a second claim for the index medication within 60 days after cohort entry&#xD;
        to ensure primary adherence of index therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The study cohort will include all patients who initiate Tiotropium/ Olodaterol (Tio/Olo) or&#xD;
        Tiotropium (Tio) during the patient selection period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The following exclusion criteria will then be applied to generate the unmatched cohort:&#xD;
&#xD;
          -  Aged &lt;40 years on cohort entry.&#xD;
&#xD;
          -  Any LAMA, LABA, or ICS maintenance therapy (alone or in combination) during the&#xD;
             180-day baseline period prior to cohort entry for maintenance treatment and duration&#xD;
             &gt;30 days, or any prescription within the 30 days prior to cohort entry.&#xD;
&#xD;
          -  Patients without continuous enrolment (days since first inpatient/ outpatient&#xD;
             encounter in the data) during the baseline period.&#xD;
&#xD;
          -  No prior diagnosis of COPD [International Classification of Diseases (ICD)-10: J41*,&#xD;
             J43*, J44* and doubt (UTAGAIFLG) = 0 (no)]&#xD;
&#xD;
          -  Patients without a second prescription claim of their index medication within 60 days&#xD;
             after the cohort entry date.&#xD;
&#xD;
          -  Diagnosis of asthma [ICD-10: J45* and doubt (UTAGAIFLG) = 0 (no)] during the baseline&#xD;
             period.&#xD;
&#xD;
          -  Diagnosis of lung cancer [ICD-10: C34*, D02.2, Z80.1, Z85.1 and doubt (UTALAIFLG) = 0&#xD;
             (no)] or lung transplant (Health claim code: 150317670, 150322510, 150322610,&#xD;
             150336510, 150336610, 150336710, 150399270) prior to the cohort entry date using all&#xD;
             available data.&#xD;
&#xD;
          -  Patients who initiate both Tio/Olo and Tio simultaneously on the cohort entry date.&#xD;
&#xD;
          -  Any use of triple therapy (LAMA + LABA + ICS) during the baseline period or between&#xD;
             the cohort entry date and 1 day prior to the start of follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nara Medical University</name>
      <address>
        <city>Nara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <results_first_submitted>August 3, 2021</results_first_submitted>
  <results_first_submitted_qc>August 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 30, 2021</results_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link http://mystudywindow.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04249310/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A new-user, active comparator retrospective comparative cohort study using a Japanese electronic healthcare research database.The study aims to test early intervention effectiveness of tiotropium/olodaterol compared to tiotropium in patients with chronic obstructive pulmonary disease (COPD).</recruitment_details>
      <pre_assignment_details>Only subjects that met all inclusion and none of the exclusion criteria were included in the study. The enrolled patients were matched into 2 (not mutually exclusive) cohorts: 1) basic propensity score (PS) cohort, 2) high dimensional propensity score (hdPS) cohort.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium/Olodaterol (Spiolto®)</title>
          <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium/Olodaterol (Tio/Olo) during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium (Spiriva®)</title>
          <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1436"/>
                <participants group_id="P2" count="5352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PS-matched Cohort</title>
              <participants_list>
                <participants group_id="P1" count="1412"/>
                <participants group_id="P2" count="1412"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>hdPS-matched Cohort</title>
              <participants_list>
                <participants group_id="P1" count="1302"/>
                <participants group_id="P2" count="1302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1436"/>
                <participants group_id="P2" count="5352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients included on the Japanese electronic, record based health care database (MDV) between September 2015 and December 2019 using either a combination of tiotropium/olodaterol or tiotropium alone - unmatched cohort.</population>
      <group_list>
        <group group_id="B1">
          <title>Tiotropium/Olodaterol (Spiolto®)</title>
          <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium/Olodaterol (Tio/Olo) during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium (Spiriva®)</title>
          <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1436"/>
            <count group_id="B2" value="5352"/>
            <count group_id="B3" value="6788"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>All patients included on the Japanese electronic, record based health care database (MDV) between September 2015 and December 2019 using either a combination of tiotropium/olodaterol or tiotropium alone - unmatched cohort.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1436"/>
                    <count group_id="B2" value="5352"/>
                    <count group_id="B3" value="6788"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.16" spread="8.41"/>
                    <measurement group_id="B2" value="75.56" spread="8.90"/>
                    <measurement group_id="B3" value="75.48" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>All patients included on the Japanese electronic, record based health care database (MDV) between September 2015 and December 2019 using either a combination of tiotropium/olodaterol or tiotropium alone - unmatched cohort.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1436"/>
                    <count group_id="B2" value="5352"/>
                    <count group_id="B3" value="6788"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="779"/>
                    <measurement group_id="B3" value="942"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1273"/>
                    <measurement group_id="B2" value="4573"/>
                    <measurement group_id="B3" value="5846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Triple Therapy Initiation</title>
        <description>Time to triple therapy initiation (first event per patient) defined as any fixed dose combination of Long-acting muscarinic antagonists (LAMA) / Long-acting beta agonist (LABA) / Inhaled Corticosteroid (ICS) or any concurrent use for 30 consecutive days of the following:&#xD;
any LAMA/LABA fixed dose combination + any ICS single formulation&#xD;
any LAMA single formulation + any LABA/ICS fixed dose combination&#xD;
any LAMA single formulation + any LABA single formulation + any ICS single formulation.&#xD;
Patients will be censored if they had an occurrence of any of the following: outcome (initiation of triple therapy), death, or end of data. The analysis will use an intention-to-treat censoring approach, which does not account for treatment change.</description>
        <time_frame>From index date (cohort entry date) until first occurence of event, up to 42 months.</time_frame>
        <population>All patients included on the Japanese electronic, record based health care database (MDV) between September 2015 and December 2019 using either a combination of tiotropium/olodaterol or tiotropium alone - High dimensional propensity score (hdPS) matched cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium/Olodaterol (Spiolto®)</title>
            <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium/Olodaterol (Tio/Olo) during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (Spiriva®)</title>
            <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Triple Therapy Initiation</title>
          <description>Time to triple therapy initiation (first event per patient) defined as any fixed dose combination of Long-acting muscarinic antagonists (LAMA) / Long-acting beta agonist (LABA) / Inhaled Corticosteroid (ICS) or any concurrent use for 30 consecutive days of the following:&#xD;
any LAMA/LABA fixed dose combination + any ICS single formulation&#xD;
any LAMA single formulation + any LABA/ICS fixed dose combination&#xD;
any LAMA single formulation + any LABA single formulation + any ICS single formulation.&#xD;
Patients will be censored if they had an occurrence of any of the following: outcome (initiation of triple therapy), death, or end of data. The analysis will use an intention-to-treat censoring approach, which does not account for treatment change.</description>
          <population>All patients included on the Japanese electronic, record based health care database (MDV) between September 2015 and December 2019 using either a combination of tiotropium/olodaterol or tiotropium alone - High dimensional propensity score (hdPS) matched cohort.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1302"/>
                <count group_id="O2" value="1302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.0" spread="123.2"/>
                    <measurement group_id="O2" value="89.5" spread="112.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
            <estimate_desc>[(Tiotropium/Olodaterol) / Tiotropium] Cox-regression was used to estimate the hazard ratios and 95% confidence intervals.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <description>Time to First Moderate or Severe COPD Exacerbation. Moderate exacerbation is defined as an outpatient visit with a diagnosed code for COPD in any field + a prescription for an oral corticosteroid or an antibiotic for respiratory infections. Severe exacerbations will be defined as a hospitalization with a primary diagnosis for COPD.&#xD;
Patients will be censored if they had an occurrence of any of the following: outcome (initiation of triple therapy), death, or end of data. The analysis will use an intention-to-treat censoring approach, which does not account for treatment change.</description>
        <time_frame>From index date until first occurence of event, up to 42 months.</time_frame>
        <population>All patients included on the Japanese electronic, record based health care database (MDV) between September 2015 and December 2019 using either a combination of tiotropium/olodaterol or tiotropium alone - High dimensional propensity score (hdPS) matched cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium/Olodaterol (Spiolto®)</title>
            <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium/Olodaterol (Tio/Olo) during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (Spiriva®)</title>
            <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <description>Time to First Moderate or Severe COPD Exacerbation. Moderate exacerbation is defined as an outpatient visit with a diagnosed code for COPD in any field + a prescription for an oral corticosteroid or an antibiotic for respiratory infections. Severe exacerbations will be defined as a hospitalization with a primary diagnosis for COPD.&#xD;
Patients will be censored if they had an occurrence of any of the following: outcome (initiation of triple therapy), death, or end of data. The analysis will use an intention-to-treat censoring approach, which does not account for treatment change.</description>
          <population>All patients included on the Japanese electronic, record based health care database (MDV) between September 2015 and December 2019 using either a combination of tiotropium/olodaterol or tiotropium alone - High dimensional propensity score (hdPS) matched cohort.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1302"/>
                <count group_id="O2" value="1302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.3" spread="108.7"/>
                    <measurement group_id="O2" value="118.8" spread="105.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.6" spread="107.4"/>
                    <measurement group_id="O2" value="139.0" spread="121.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.0" spread="112.5"/>
                    <measurement group_id="O2" value="134.5" spread="107.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate or Severe COPD Exacerbation</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>[(Tiotropium/Olodaterol) / Tiotropium] Cox regression was used to estimate the hazard ratios and 95% confidence intervals.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate COPD Exacerbation</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>[(Tiotropium/Olodaterol) / Tiotropium] Cox regression was used to estimate the hazard ratios and 95% confidence intervals.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Severe COPD Exacerbation</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>[(Tiotropium/Olodaterol) / Tiotropium] Cox regression was used to estimate the hazard ratios and 95% confidence intervals.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</title>
        <description>Number of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations.&#xD;
Moderate exacerbation is defined as an outpatient visit with a diagnosed code for COPD in any field + a prescription for an oral corticosteroid or an antibiotic for respiratory infections. Severe exacerbations will be defined as a hospitalization with a primary diagnosis for COPD.&#xD;
Patients will be censored if they had an occurrence of any of the following: outcome (initiation of triple therapy), death, or end of data. The analysis will use an intention-to-treat censoring approach, which does not account for treatment change.</description>
        <time_frame>From index date until first occurence of event, up to 42 months.</time_frame>
        <population>All patients included on the Japanese electronic, record based health care database (MDV) between September 2015 and December 2019 using either a combination of tiotropium/olodaterol or tiotropium alone - Unmatched cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium/Olodaterol (Spiolto®)</title>
            <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium/Olodaterol (Tio/Olo) during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (Spiriva®)</title>
            <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</title>
          <description>Number of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations.&#xD;
Moderate exacerbation is defined as an outpatient visit with a diagnosed code for COPD in any field + a prescription for an oral corticosteroid or an antibiotic for respiratory infections. Severe exacerbations will be defined as a hospitalization with a primary diagnosis for COPD.&#xD;
Patients will be censored if they had an occurrence of any of the following: outcome (initiation of triple therapy), death, or end of data. The analysis will use an intention-to-treat censoring approach, which does not account for treatment change.</description>
          <population>All patients included on the Japanese electronic, record based health care database (MDV) between September 2015 and December 2019 using either a combination of tiotropium/olodaterol or tiotropium alone - Unmatched cohort.</population>
          <units>Number of Exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1436"/>
                <count group_id="O2" value="5352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate or Severe Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.33"/>
                    <measurement group_id="O2" value="0.08" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.22"/>
                    <measurement group_id="O2" value="0.04" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.24"/>
                    <measurement group_id="O2" value="0.05" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>As this is a non-interventional study with secondary use of data retrieved from a Japanese database, safety monitoring and safety reporting on an individual case level is not applicable. All-Cause Mortality, Serious Adverse Events and Other Adverse Events are not collected in the database. &quot;0&quot; total Number of Participants at Risk means &quot;All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed&quot;.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tiotropium/Olodaterol (Spiolto®)</title>
          <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium/Olodaterol (Tio/Olo) during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium (Spiriva®)</title>
          <description>All patients with chronic obstructive pulmonary disease (COPD), included in the Japanese electronic healthcare research database (MDV Japan), who initiated Tiotropium during the patient selection period (September 2015 to December 2018). Patients were followed up a maximum of 360 days or until end of study period (March 2019, end of available data).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Centre</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

